We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Clare
Lyon
cel60@medschl.cam.ac.uk
Chenqu
Suo
chenqu.suo@nhs.net
Sarah
Teichmann
sat1003@cam.ac.uk
Clare
Lyon
cel60@medschl.cam.ac.uk
Other osteopathies
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Rare paediatric inflammatory conditions caused by single gene changes have been studied extensively to date. However, there is a distinct lack of research on their polygenic counterparts, where disease can occur after multiple gene changes or due to currently undefined environmental effects.
In this study we will focus on the condition chronic recurrent multifocal osteomyelitis (CRMO). CRMO is a disease where the patients’ immune system attacks their bones by mistake (autoinflammation), causing bone pain and swelling. The cause of CRMO remains poorly understood and therefore makes it difficult to diagnose. Currently, it is diagnosed by excluding other conditions first and involves invasive procedures, leading to delays in diagnosis and treatment.
This study will use 3 different types of cutting-edge single-cell technologies to look at individual cells in diseased tissues (bone and blood); the results of which will construct a detailed map of what these cells are and how they interact. A profile of the diseased bone and blood will be compared to control bone and blood. This will identify potential underlying causes of CRMO, enabling discovery of tests for diagnosis and ways to monitor the disease. These deep insights will in turn pave the way for development of future treatments based on an understanding on how the cells work and interact in the process of autoinflammation.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Clinical Laboratory Study;
You can take part if:
You may not be able to take part if:
- Consent not provided - Preferentially, individuals who are not on corticosteroid, DMARD (disease-modifying antirheumatic drug), or biologics for the last 6 weeks. However, this is not a strict exclusion criteria.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Clare
Lyon
cel60@medschl.cam.ac.uk
Sarah
Teichmann
sat1003@cam.ac.uk
Chenqu
Suo
chenqu.suo@nhs.net
Clare
Lyon
cel60@medschl.cam.ac.uk
The study is sponsored by CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST and funded by ROSETREES .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 61102
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
